AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$TAK

Plump Andrew Stewart sold $2.1M of TAK (indirect holdings)

Plump Andrew Stewart (President, R&D) sold 116,191 indirectly-held shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $18.49 ($2.15M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Plump Andrew Stewart
Published Sep 4, 2026, 1:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 2:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TAK
Bearish
medium confidence
Mentioned
$TAK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKBearishLow
01

Why it matters

The disclosed sale is the first public report of this insider transaction, providing new data for investors.

02

Market read

Primary insider sale adds modest new information; limited trading relevance.

03

What to watch

Potential upcoming R&D milestones or pipeline news may outweigh the insider sell.

Relevance 5/10Novelty 4/10Timing: sale filed on 2026‑09‑03, transaction dated 2026‑09‑02

Background

Form 4 filing discloses insider transactions; Takeda is a large Japanese pharma listed in the US.

Company-level read

Ticker impact

$TAKBearishMedium confidence
Context

President of R&D sold 116,191 shares for $2.15M via a 10b5‑1 plan.

Expected impact

Potential slight dip or flat price action as investors digest the sell.

Evidence & confidence

Sale is a primary disclosure but amount is small relative to Takeda's market cap, so impact is limited.

Market effects

Sector

Minimal effect on pharma sector; insider sales are routine.

Regional

No significant regional impact beyond Takeda's share price.

Global

Limited relevance to global markets.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a signal of weakness.

Key entities

  • Company
    Takeda Pharmaceutical Co Ltd

    Japanese pharmaceutical company listed on NYSE under ticker TAK.

  • Insider
    Plump Andrew Stewart

    President of R&D at Takeda, reporting a sale of shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min